Omega-3 fatty acids: potential role in the management of early Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Omega-3 fatty acids are essential for brain growth and development. They play an important role throughout life, as critical modulators of neuronal function and regulation of oxidative stress mechanisms, in brain health and disease. Docosahexanoic acid (DHA), the major omega-3 fatty acid found in neurons, has taken on a central role as a target for therapeutic intervention in Alzheimer's disease (AD). A plethora of in vitro, animal model, and human data, gathered over the past decade, highlight the important role DHA may play in the development of a variety of neurological and psychiatric disorders, including AD. Cross sectional and prospective cohort data have demonstrated that reduced dietary intake or low brain levels of DHA are associated with accelerated cognitive decline or the development of incipient dementia, including AD. Several clinical trials investigating the effects of omega-3 fatty acid supplementation in AD have been completed and all failed to demonstrate its efficacy in the treatment of AD. However, these trials produced intriguing data suggesting that the beneficial effects of omega-3 fatty acid supplementation may depend on the stage of disease, other dietary mediators, and apolipoprotein E status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“DHA and Aβ The amyloid cascade hypothesis of AD pathogenesis holds as a basic tenet the early formation of toxic amyloid-beta (Aβ) fragments from the normal cellular, transmembrane, amyloid precursor protein (APP).(44,45) Release of toxic Aβ fragments leads to the early formation of soluble dimeric and oligomeric aggr…”
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
The role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Wilson, R. S., Aggarwal, N., & Schneider, J. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.940 · Cited by 1,135 · cited 1×
“Morris and colleagues presented data from a FFQ administration to 815 subjects in the Chicago Housing and Aging Project (CHAP) in 2003.(98) The study concluded that participants who consumed fish once a week or more had a 60% reduced risk of AD compared to those who rarely, or never, ate fish.”
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Dietary fat intake and the risk of incident dementia in the Rotterdam study
Kalmijn, S., Launer, L. J., Ott, A., Witteman, J. C. M., Hofman, A., & Breteler, M. M. B. (1997) · Annals of Neurology · doi:10.1002/ana.410420514 · Cited by 895 · cited 1×
“In 1997, Kalmijn and colleagues published data from the Rotterdam Study that included 5,386 individuals that were non-demented at baseline.(89) All completed a FFQ as”
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Dietary patterns and risk of dementia: The Three-City cohort study
Barberger-Gateau, P., Raffaitin, C., Letenneur, L., Berr, C., Tzourio, C., Dartigues, J. F., & Alpérovitch, A. (2007) · Neurology · doi:10.1212/01.wnl.0000278116.37320.52 · Cited by 700
Schaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S., Robins, S. J., Au, R., Tucker, K. L., Kyle, D. J., Wilson, P. W. F., & Wolf, P. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1545 · Cited by 686 · cited 1×
“1 years.(101) Over the study period, 99 incident cases of dementia were observed and increased baseline DHA levels were associated with a reduced risk of incident dementia in this cohort.”
Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
Lavie, C. J., Milani, R. V., Mehra, M. R., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.084 · Cited by 644
Shi, F., Liu, B., Zhou, Y., Yu, C., & Jiang, T. (2009) · Hippocampus · doi:10.1002/hipo.20573 · Cited by 470
Fish Consumption and Cognitive Decline With Age in a Large Community Study
Morris, M. C., Evans, D. A., Tangney, C. C., Bienias, J. L., & Wilson, R. S. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.noc50161 · Cited by 428
Docosahexaenoic acid promotes neurogenesis in vitro and in vivo
Kawakita, E., Hashimoto, M., & Shido, O. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.021 · Cited by 410
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
van Gelder, B. M., Tijhuis, M., Kalmijn, S., & Kromhout, D. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.1142 · Cited by 346
Omega‐3 Dietary Supplements and the Risk of Cardiovascular Events: A Systematic Review
Marik, P. E., & Varon, J. (2009) · Clinical Cardiology · doi:10.1002/clc.20604 · Cited by 328
Diet and risk of dementia: Does fat matter?: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2002) · Neurology · doi:10.1212/01.wnl.0000038345.77753.46 · Cited by 324
Hashimoto, M., Tanabe, Y., Fujii, Y., Kikuta, T., Shibata, H., & Shido, O. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.3.549 · Cited by 288 · cited 1×
“62 The experimental paradigm for treatment is as easy as altering the fatty acid composition of the diet used to feed the animals.”
Atherosclerosis and AD: Analysis of data from the US National Alzheimer’s Coordinating Center
Honig, L. S., Kukull, W., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000150886.50187.30 · Cited by 284
Beydoun, M. A., Kaufman, J. S., Satia, J. A., Rosamond, W., & Folsom, A. R. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/85.4.1103 · Cited by 253
Mixed Dementia: Epidemiology, Diagnosis, and Treatment
Zekry, D., Hauw, J., & Gold, G. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50367.x · Cited by 243 · cited 1×
“68 The interplay between PUFAs, cholesterol, CVD, and their interrelationship with the development of AD is a topic of extreme interest in the field.”
F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease
Nourooz‐Zadeh, J., Liu, E. H. C., Yhlen, B., Änggåard, E. E., & Halliwell, B. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720734.x · Cited by 187
Apolipoprotein E and cholesterol in aging and disease in the brain
de Chaves, E. P., Narayanaswami, V., Christoffersen, C., & Nielsen, L. B. (2008) · Future Lipidology · doi:10.2217/17460875.3.5.505 · Cited by 164
Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging
Kröger, E., Verreault, R., Carmichael, P.-H., Lindsay, J., Julien, P., Dewailly, É., Ayotte, P., & Laurin, D. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26987 · Cited by 149 · cited 1×
“In 2009, the CHSA published an updated report in 663 cognitively normal subjects at baseline, followed prospectively that included 149 incident cases of dementia at study end.(93) This study again failed to show a significant association of baseline plasma PUFA levels and risk of incident cognitive decline in this pop…”
Marzolo, M.-P., & Bu, G. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.10.005 · Cited by 122 · cited 1×
“Cholesterol may directly increase the activity of β- and γ-secretases.(77,78) High cholesterol exposure increases Aβ production, whereas low cholesterol exposure decreases Aβ production in cell culture and in transgenic mouse models of AD.”
Schaeffer, E. L., Forlenza, O. V., & Gattaz, W. F. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1351-0 · Cited by 71
Cited by
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Janssen, C. I. F., & Kiliaan, A. J. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2013.10.002 · Cited by 514
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Insulin and Insulin Resistance in Alzheimer’s Disease
Sędzikowska, A., & Szablewski, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189987 · Cited by 377
Shinto, L., Quinn, J., Montine, T., Dodge, H. H., Woodward, W., Baldauf-Wagner, S., Waichunas, D., Bumgarner, L., Bourdette, D., Silbert, L., et al. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130722 · Cited by 288
Metadata
- Authors
- Jicha, G.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2010-03
- Volume
- 5
- Pages
- 45
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W2087040730
- Cited by
- 155
- References
- 29
- FWCI
- 14.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.